by admin | Feb 4, 2019 | Press Releases
New York, NY., February 4th, 2019 — ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the U.S. and Canada) to evaluate the combination of ENB-003, a first-in class endothelin B receptor (“ETBR”) inhibitor and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a Phase 1/2 trial in patients with advanced solid tumors. The open-label, dose-escalation and expansion Phase 1/2 study will enroll patients with anti-PD-1 resistant malignant melanoma, platinum-resistant ovarian or pancreatic cancer with previous treatment failure. The dose escalation phase of the trial will evaluate the safety and tolerability of various doses of ENB-003 as a monotherapy and in combination with KEYTRUDA. The dose expansion will evaluate preliminary efficacy, safety and tolerability of the selected dose of ENB-003 combined with KEYTRUDA as well as changes in immunohistochemistry and pharmacodynamic biomarkers after administration of ENB-003. “We are thrilled to collaborate with Merck, an established leader in the field of cancer immunotherapy,” said Sumayah Jamal, M.D., Ph.D., President and CSO of ENB Therapeutics. “ENB-003 has both antitumor and immune-modulatory effects and augments the efficacy of anti-PD-1 inhibition in animal models. We are optimistic about exploring the combination of ENB-003 and KEYTRUDA .” Under the terms of the agreement, ENB Therapeutics will sponsor the ENB-003 and KEYTRUDA clinical study. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. About ENB Therapeutics ENB Therapeutics is a biopharmaceutical company pioneering the development of selective inhibitors of the endothelin B receptor (“ETBR”) to reverse the...
by admin | Sep 21, 2018 | Press Releases
New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the company’s lead investigational drug compound, ENB-003,a first-in-class, selective inhibitor of the endothelin B receptor (“ETBR”) through pre-clinical and early clinical development for the treatment of immunotherapy-resistant cancers. Remiges Ventures served as lead investor for the financing with participation from New York State Development, BioAdvance and Alexandria Ventures. “We are extremely gratified to have attracted a leading group of investors to complete our Series A financing who recognize the potential of ENB-003 to overcome resistance to immunotherapy across multiple tumor types and indications,” said Sumayah Jamal, Founder, President and Chief Scientific Officer of ENB. “We have already demonstrated robust pre-clinical efficacy in relevant mouse models across multiple resistant cancers and a favorable safety profile. We now have the capital necessary to advance ENB-003 into Phase 1 clinical trials during the second half of 2019.” Taro Inaba, Managing Partner at Remiges, added, “We believe that ENB Therapeutics’ novel compounds have the potential to enhance the efficacy of immunotherapies and potentially prolong patient survival and thereby address the high unmet medical need which still exists despite the successful development and widespread use of immunotherapies. Therefore, we are very pleased to have the opportunity to support the continued clinical development of ENB-003, which could improve the lives of patients with cancer.” About ENB Therapeutics ENB Therapeutics is a biopharmaceutical company pioneering the development of selective inhibitors of the endothelin B receptor (“ETBR”) to reverse...
by admin | Apr 25, 2016 | Uncategorized
ENB was selected as one of 33 companies to present at this year’s Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC’s Time Warner Center. Representative entrepreneurs will give a 15-minute pitch to a panel of judges made up of investors and other experts. This will be followed by 5 minutes of Q&A and 5 minutes of non-rebuttal feedback from the panel. Pitches will be evaluated and scored on a range of important business and scientific criteria. Leading scorers and winners will be announced during the keynote program later in the day. Judges for this year’s pitch fest hail from Merck, Sanofi, Pfizer, J&J, Lilly, leading VC law and accounting, and many...
by admin | Apr 25, 2016 | Uncategorized
April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals. ENB’s investor presentation was one of 3 chosen for the event. ENB’s CSO Dr. Sumayah Jamal gave the presentation and was voted by an audience of over 100 as “Best-in-Show”. ENB is now qualified to advance to the annual “Best of the Best/People’s Choice”...
by admin | Apr 25, 2016 | Uncategorized
March, 2016 ENB Therapeutics presents poster entitled “Development of ENB-001 for the Treatment of Melanoma Brain Metastasis” at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and renowned speakers with a program designed for oncologists, dermatologists, researchers and students. The poster abstract is below: As systemic therapy improves, patients with melanoma are living longer. As a result, 44% – 76% of all those diagnosed with advanced melanoma are developing, and dying from, melanoma that metastasizes to the central nervous system (CNS), specifically the brain. This catastrophic event is the most common cause of death in patients with melanoma and there are no approved therapies specifically for melanoma with CNS involvement. A common cause of resistance to melanoma treatment is upregulation of the endothelin B receptor (ETBR). ENB-001 is a small molecule that precisely targets the ETBR, inhibiting downstream RAF, MEK and AKT activity. ENB-001 has achieved proof of concept in animal models of CNS melanoma as well as extra-CNS melanoma metastases. Efficacy in preclinical studies for glioblastoma and squamous cell carcinoma has also been demonstrated. ENB-001, in contrast to approved MEK inhibitors, also has immunostimulatory effects, enhancing T-cell homing and adhesion to cancer cell vasculature. We have partnered with a drug formulation company that has a proprietary nanoparticle intranasal delivery system that bypasses the blood brain barrier, and will be used to deliver ENB-001 directly to the central nervous system. The development of ENB-001 will have a significant impact for patients with CNS melanoma. Further opportunities include the treatment of non-CNS melanoma metastatic disease, other malignancies, and the development of...
by admin | Apr 25, 2016 | Uncategorized
March 2016 Sumayah Jamal, MD-PhD, Co-founder and CSO of ENB was accepted into the 2016 Pharma Class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science companies seeking seed and growth funding to fuel expansion and product development. Companies selected for the Pharma track will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners. Springboard vetted companies have an impressive 83% funding rate and have raised almost $7B since the program’s inception 15 years ago. ENB is honored to have been chosen as a Springboard...
by admin | Jan 30, 2016 | Uncategorized
January 21,2016- FDA awards ENB lead product ENB001 Orphan Drug Designation for Stage IIB- Stage IV melanoma. This represents a major milestone in our development program for ENB001 which now qualifies for various development incentives including tax credits for clinical trials, seven year marketing exclusivity in the US following approval, and a fast track for the FDA to evaluate registration...
by admin | Jan 9, 2016 | Uncategorized
December, 2015. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. ENB has been chosen to attend as a presenting company for this year’s...
by admin | Jan 9, 2016 | Uncategorized
November, 2015 The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. The pipeline café features academic innovators who are hand selected to present their discoveries, which are available for partnering. ENB was invited this year to be a Pipeline Cafe...
by admin | Jun 16, 2015 | Uncategorized
We are currently in our Series A round of funding. Click here to view our investor materials.
